Artgen Biotech PJSC (MIC:ABIO) Cyclically Adjusted Book per Share: ₽3.90 (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIC:ABIO Artgen Biotech PJSC MIC:ABIO
17 GF Score
Price ₽44.46
View Full Analysis

What is Artgen Biotech PJSC Cyclically Adjusted Book per Share?

Artgen Biotech PJSC MIC:ABIO +0.50% 17 Cyclically Adjusted Book per Share is ₽3.90 as of Jun. 2023. GuruFocus rates MIC:ABIO with a GF Score™ of 17/100.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Artgen Biotech PJSC's adjusted book value per share data for the fiscal year that ended in Dec. 2022 was ₽4.179. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is ₽3.90 for the trailing ten years ended in Dec. 2022.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-08-29), Artgen Biotech PJSC's current stock price is ₽ 44.46. Artgen Biotech PJSC's Cyclically Adjusted Book per Share for the fiscal year that ended in Dec. 2022 was ₽3.90. Artgen Biotech PJSC's Cyclically Adjusted PB Ratio of today is 11.40.


Artgen Biotech PJSC  (MIC:ABIO) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Artgen Biotech PJSC's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=44.46/3.90
=11.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Artgen Biotech PJSC Cyclically Adjusted Book per Share Related Terms


Artgen Biotech PJSC Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Artgen Biotech PJSC's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Artgen Biotech PJSC Cyclically Adjusted Book per Share Chart

Artgen Biotech PJSC Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.63 4.40 4.37 3.90 3.90

Artgen Biotech PJSC Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 3.90 0.00 3.90 0.00

MIC:ABIO vs VRTX, REGN, SGEN: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Artgen Biotech PJSC's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Artgen Biotech PJSC Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Artgen Biotech PJSC's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Artgen Biotech PJSC's Cyclically Adjusted PB Ratio falls into.


MIC:ABIO
17GF Score
Artgen Biotech PJSC MIC:ABIO
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Artgen Biotech PJSC Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Artgen Biotech PJSC's adjusted Book Value per Share data for the fiscal year that ended in Dec. 2022 was:

Adj_Book=Book Value per Share /CPI of Dec. 2022 (Change)*Current CPI (Dec. 2022)
=4.179/231.9000*231.9000
=4.179

Current CPI (Dec. 2022) = 231.9000.

Artgen Biotech PJSC Annual Data

Book Value per Share CPI Adj_Book
201312 4.690 124.900 8.708
201412 4.522 139.000 7.544
201512 3.835 157.000 5.665
201612 2.051 165.400 2.876
201712 0.683 169.600 0.934
201812 0.360 176.800 0.472
201912 1.478 182.200 1.881
202012 2.590 191.100 3.143
202112 3.199 207.200 3.580
202212 4.179 231.900 4.179

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of ₽3.90 mean?
Artgen Biotech PJSC (MIC:ABIO) has a Cyclically Adjusted Book per Share of ₽3.90 as of Jun. 2023. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Artgen Biotech PJSC and its competitors.
Is Artgen Biotech PJSC's Cyclically Adjusted Book per Share too high?
Artgen Biotech PJSC's current Cyclically Adjusted Book per Share is ₽3.90. Overall, Artgen Biotech PJSC has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Artgen Biotech PJSC's Cyclically Adjusted Book per Share compare to VRTX and REGN?
Artgen Biotech PJSC's Cyclically Adjusted Book per Share of ₽3.90 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Artgen Biotech PJSC and its competitors. Artgen Biotech PJSC's current Cyclically Adjusted Book per Share is ₽3.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artgen Biotech PJSC stock overvalued right now?
Artgen Biotech PJSC (MIC:ABIO) has a current Cyclically Adjusted Book per Share of ₽3.90. The current Cyclically Adjusted Book per Share is ₽3.90. Artgen Biotech PJSC's overall GF Score™ is 17/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Artgen Biotech PJSC (MIC:ABIO), the current Cyclically Adjusted Book per Share is ₽3.90 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Artgen Biotech PJSC Business Description

Address Prospect of the 60th Anniversary, Moscow, RUS, 117036
Artgen Biotech PJSC is a biotechnology company. It is engaged in the drug discovery, research and development and marketing of proprietary products and services in the field of regenerative medicine, bio-insurance, medical genetics, including reproductive genetics, gene therapy, and biopharmaceutics. The company has developed Neovasculgen, which is a gene therapy drug for the treatment of Peripheral Arterial Disease, including Critical Limb Ischemia and also develops SPRS therapy which entails the use of autologous dermal fibroblasts to repair skin damage due to aging and other structural changes.
17GF Score

Get the complete analysis for MIC:ABIO

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₽44.46
Price